This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Edwards Lifesciences's JenaValve deal faces in-depth Austrian review

By Andrew Boyce ( October 28, 2024, 13:29 GMT | Insight) -- Edwards Lifesciences's takeover of JenaValve Technology, a US medical devices company making an innovative treatment for heart disease, has triggered an in-depth competition investigation in Austria. The probe adds to the scrutiny of the deal in Europe, with a phase II probe in Germany already underway.Edwards Lifesciences is facing an in-depth Austrian probe into its plan to take over JenaValve Technology, a US medical devices company making an innovative treatment for heart disease....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections